| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:CRA-026440 hydrochloride CAS:847459-98-7 Purity:99% Package:1mg;5mg;10mg
|
| Company Name: |
Beijing Boorsen Biotechnology Co., Ltd
|
| Tel: |
400-901-9800 18611424007 |
| Email: |
cis@bioss.com.cn |
| Products Intro: |
Product Name:CRA-026440 hydrochloride Purity:0.9978 Package:1mg;1mL x 10mM (in DMSO) Remarks:D55869
|
| Company Name: |
RD International Technology Co., Limited
|
| Tel: |
18024082417 |
| Email: |
market@ubiochem.com |
| Products Intro: |
Product Name:HDAC/BET-IN-1 CAS:847459-98-7 Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
1H-Indole-2-carboxamide, 5-[2-(dimethylamino)ethoxy]-N-[3-[4-[(hydroxyamino)carbonyl]phenyl]-2-propyn-1-yl]-, hydrochloride (1:1) manufacturers
|
| | 1H-Indole-2-carboxamide, 5-[2-(dimethylamino)ethoxy]-N-[3-[4-[(hydroxyamino)carbonyl]phenyl]-2-propyn-1-yl]-, hydrochloride (1:1) Basic information |
| | 1H-Indole-2-carboxamide, 5-[2-(dimethylamino)ethoxy]-N-[3-[4-[(hydroxyamino)carbonyl]phenyl]-2-propyn-1-yl]-, hydrochloride (1:1) Chemical Properties |
| form | Solid | | color | White to off-white |
| | 1H-Indole-2-carboxamide, 5-[2-(dimethylamino)ethoxy]-N-[3-[4-[(hydroxyamino)carbonyl]phenyl]-2-propyn-1-yl]-, hydrochloride (1:1) Usage And Synthesis |
| Uses | CRA-026440 hydrochloride is a potent, broad-spectrum HDAC (HDAC) inhibitor. The Ki values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities[1]. CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | in vivo | CRA-026440 hydrochloride (100 mg/kg; i.v.; daily; for three consecutive days) results in a statistically significant reduction in tumor growth in mice harboring HCT116 or U937 human tumor xenografts[1]. | Animal Model: | HCT-116 tumor-bearing nude mice[1] | | Dosage: | 100 mg/kg | | Administration: | i.v.; daily; for three consecutive days | | Result: | Resulted in a statistically significant reduction in tumor growth. |
| | IC 50 | HDAC1: 4 nM (IC50); HDAC2: 14 nM (IC50); HDAC3/SMRT: 11 nM (IC50); HDAC6: 15 nM (IC50); HDAC8: 7 nM (IC50); HDAC10: 20 nM (IC50) | | References | [1] [1]Cao ZA, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther. 2006 Jul;5(7):1693-701. DOI:10.1158/1535-7163.MCT-06-0042 |
| | 1H-Indole-2-carboxamide, 5-[2-(dimethylamino)ethoxy]-N-[3-[4-[(hydroxyamino)carbonyl]phenyl]-2-propyn-1-yl]-, hydrochloride (1:1) Preparation Products And Raw materials |
|